| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/17/1996 | EP0692028A1 Pharmaceuticals based on papillomaviruses |
| 01/17/1996 | EP0692027A1 Expression of beta-2-microglobulin in pichia pastoris |
| 01/17/1996 | EP0691988A1 Inhibitor of stem cell proliferation and uses thereof |
| 01/17/1996 | EP0691981A1 Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides |
| 01/17/1996 | EP0691851A1 A method to produce a substance to inhibit cell penetration, and a contraceptive to prevent conception, and a thrombus, prostate and aids vaccine and medicine |
| 01/17/1996 | EP0691848A1 Immunopotentiative and infection-protective agent, containing two or more bacillus, egg white and garlic |
| 01/17/1996 | EP0521916B1 Use of il-4 to enhance immune response to infectious antigenic challenges |
| 01/17/1996 | EP0436526B1 Use of antibodies to angiogenin: immunotherapeutic agents |
| 01/16/1996 | US5484907 Nucleotides coding for the extracellular membrane-bound segment of IgA |
| 01/16/1996 | US5484891 Pure polypeptide able to hybridize under low stringency conditions; glycoproteins |
| 01/16/1996 | US5484724 DNA encoding GLSI |
| 01/16/1996 | US5484719 Vaccines produced and administered through edible plants |
| 01/16/1996 | US5484592 Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs |
| 01/16/1996 | US5484591 Method for treating gram negative bacterial infections in humans |
| 01/15/1996 | CA2153858A1 Virus-safe monomeric human immunoglobulin a and methods for its production |
| 01/15/1996 | CA2153760A1 Marek's disease virus vaccine |
| 01/14/1996 | CA2153720A1 Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide |
| 01/11/1996 | WO1996000791A1 Recombinant infectious laryngotracheitis virus and vaccine |
| 01/11/1996 | WO1996000587A1 Aav capsid vehicles for molecular transfer |
| 01/11/1996 | WO1996000583A1 Polynucleotide vaccine for papillomavirus |
| 01/11/1996 | DE4423392A1 Verfahren zur Identifizierung antigener Peptide A method for identifying antigenic peptides |
| 01/11/1996 | DE4422238A1 Verfahren zur Isolierung einer Antigenpräparation A method for isolating an antigenic preparation |
| 01/11/1996 | CA2193802A1 Aav capsid vehicles for molecular transfer |
| 01/10/1996 | EP0691404A2 Improved vaccines for the immunisation against TBE-Virusinfections and method for their preparation |
| 01/10/1996 | EP0691350A2 uPA binding sites on domain 2+3 on uPAR and antibodies reactive therewith |
| 01/10/1996 | EP0691348A1 Immunogenic compositions prepared from adenylate cyclase of B. Parapertussis |
| 01/10/1996 | EP0691131A1 Babesia vaccine |
| 01/10/1996 | EP0690991A1 Novel anticoagulant cofactor activity |
| 01/10/1996 | EP0690990A1 Parvovirus receptors and methods of use |
| 01/10/1996 | EP0690924A1 Anti-microbial agents and screening method therefor |
| 01/10/1996 | EP0690918A1 Protein tyrosine phosphatase ptp-s31 |
| 01/10/1996 | EP0690917A1 Recombinant epstein-barr virus protein and its use in vaccine |
| 01/10/1996 | EP0690915A1 Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof |
| 01/10/1996 | EP0690914A1 Allergenic protein and peptides from house dust mite and uses therefor |
| 01/10/1996 | EP0690912A1 Recombinant avian adenovirus vector |
| 01/10/1996 | EP0690875A1 Botulinum toxin polypeptides and their use as vaccine enhancing agents |
| 01/10/1996 | EP0690871A1 Growth differentiation factor-5 |
| 01/10/1996 | EP0690725A1 Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells |
| 01/10/1996 | EP0690724A1 Chlamydia vaccine and process |
| 01/10/1996 | EP0690723A1 Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides |
| 01/10/1996 | EP0690722A1 Composition and method for reducing toxicity of biologically-active factors |
| 01/10/1996 | EP0558529B1 Pharmaceutical preparation for the treatment of prolonged coagulation time |
| 01/10/1996 | EP0556241B1 Mycobacterium vaccae in the treatment of uveitis |
| 01/10/1996 | EP0493433B1 Method for improving human monoclonal antibody production and cells used therein |
| 01/10/1996 | CN1030642C Method for preparation of chicken Newcastle disease and pox coupled live vaccine |
| 01/09/1996 | US5482853 Nuclear sequence for cellular genomes |
| 01/09/1996 | US5482713 Equine herpesvirus recombinant poxvirus vaccine |
| 01/09/1996 | US5482711 Use of Nigella sativa to increase immune function |
| 01/09/1996 | US5482709 Eimeria antigenic composition which elicits antibodies against avian coccidiosis |
| 01/09/1996 | US5482708 Leukemia, proteins are not adjacent in native protein |
| 01/09/1996 | US5482698 Detection and therapy of lesions with biotin/avidin polymer conjugates |
| 01/09/1996 | CA2153208A1 Upa binding sites on domain 2+3 on upar and antibodies reactive therewith |
| 01/04/1996 | WO1996000238A1 T cell epitopes of rye grass pollen allergen |
| 01/04/1996 | WO1996000233A1 Escherichia coli o157:h7 epithelial adhesin |
| 01/04/1996 | WO1996000084A1 Use of autoantibodies for tumor therapy and prophylaxis |
| 01/04/1996 | WO1996000083A2 Method of isolating an antigene preparation |
| 01/04/1996 | WO1996000082A1 Medical use of bromelain |
| 01/04/1996 | WO1996000081A1 Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| 01/04/1996 | WO1996000080A1 Non-antigenic amine derived polymers and polymer conjugates |
| 01/04/1996 | WO1996000007A1 Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 01/04/1996 | WO1995033059A3 Receptor for oncostatin m |
| 01/04/1996 | WO1995033049A3 Tbp2 fragments of the transferrine receptor of neisseria meningitidis |
| 01/04/1996 | WO1995030018A3 Recombinant poxviruses with foreign polynucleotides in essential regions |
| 01/04/1996 | WO1995030015A3 Isolated epstein-barr virus bzlf2 proteins that bind mhc class ii beta chains |
| 01/04/1996 | WO1995029193A3 Melanoma antigens |
| 01/04/1996 | WO1995025806A3 Packaging-deficient lentiviruses |
| 01/04/1996 | DE19523554A1 Helicobacter pylori-Impfstoffe und therapeutische Zusammensetzungen Helicobacter pylori vaccines and therapeutic compositions |
| 01/04/1996 | CA2193860A1 T cell epitopes of rye grass pollen allergen |
| 01/04/1996 | CA2193654A1 Medical use of bromelain |
| 01/04/1996 | CA2193081A1 Method of isolating an antigene preparation |
| 01/04/1996 | CA2192821A1 Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| 01/04/1996 | CA2191726A1 Non-antigenic amine derived polymers and polymer conjugates |
| 01/03/1996 | EP0690307A1 Method of determining the presence of an autoimmune antibody |
| 01/03/1996 | EP0690127A1 Compositions and methods for stimulating megakaryocyte growth and differentiation |
| 01/03/1996 | EP0690125A2 Process for induction culture of cytotoxict lymphocytes having killing activity against tumor cells |
| 01/03/1996 | EP0690071A2 Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase |
| 01/03/1996 | EP0689845A2 Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| 01/03/1996 | EP0689605A1 Hepatitis b escape mutant specific binding molecules |
| 01/03/1996 | EP0689604A1 Process for preparing cancer vaccines |
| 01/03/1996 | EP0689603A1 Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| 01/03/1996 | EP0689601A1 Production of high titer helper-free retroviruses by transient transfection |
| 01/03/1996 | EP0689600A1 Process to induce the death of tumor cells |
| 01/03/1996 | EP0689597A1 USE OF PORCINE GAL $g(a)(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES |
| 01/03/1996 | EP0689596A1 Stimulation of immune response by viral protein |
| 01/03/1996 | EP0689593A1 Inhibition of selected tumor growth with recombinant viral sector |
| 01/03/1996 | EP0689588A1 Extracellular signal-regulated kinase, sequences, and methods of production and use |
| 01/03/1996 | EP0689551A1 Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
| 01/03/1996 | EP0689550A1 Novel antimicrobial peptides from bovine neutrophils |
| 01/03/1996 | EP0689457A1 Stabilised pharmaceutical compositions and methods for preparing same |
| 01/03/1996 | EP0689455A1 Therapeutic strategies for immunoinfective cluster virus infections |
| 01/03/1996 | EP0689453A1 High molecular weight surface proteins of non-typeable haemophilus |
| 01/03/1996 | EP0689430A1 Superparamagnetic particles, process for producing the same and their use |
| 01/03/1996 | EP0689428A1 Enhanced circulation effector composition and method |
| 01/03/1996 | EP0689421A1 Reduced and controlled surface binding of biologically active molecules |
| 01/03/1996 | EP0544712B1 Neuraminidase and galactose oxidase as vaccine adjuvant |
| 01/03/1996 | EP0498851B1 Urinary tumor associated antigen, antigenic subunits uses and methods of detection |
| 01/03/1996 | EP0478602B1 Expression of tetanus toxin fragment c |
| 01/03/1996 | EP0440686B1 Peptides representing epitopic sites on r-ifn-beta, antibodies thereto, and uses thereof |
| 01/03/1996 | EP0317622B1 Prevention and treatment of retroviral disease |
| 01/03/1996 | EP0275300B1 Recombinant vaccine |